• Shin Nippon Biomedical Laboratories reported record first-half sales of JPY 17.57 billion, up 19%, for the year ending March 2027.
• Operating profit rose to JPY 1.56 billion from JPY 49 million, with revenue growth supporting the improvement.
• Ordinary profit increased 89.3% to JPY 3.08 billion, exceeding the revised forecast of JPY 2.98 billion.
• Net profit attributable to shareholders climbed 107.1% to JPY 2.19 billion, surpassing the revised forecast of JPY 1.91 billion.
• CRO projects delayed from the previous fiscal year drove sales growth; deferred TR expenses also supported profit improvement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shin Nippon Biomedical Laboratories Ltd. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.